Printer Friendly

A. L. LABORATORIES UPDATES IMPACT OF BUSINESS TRENDS ON COMPANY PERFORMANCE

 FORT LEE, N.J., Oct. l8 /PRNewswire/ -- A. L. Laboratories, Inc. (NYSE: BMD) today provided an update on trends previously discussed that are influencing the Company's performance.
 Recent regulatory approvals for Clotrimazole Vaginal cream and Epinephrine Mist, both of which will begin marketing during the fourth quarter of l993, will be important to the Company's U.S. Pharmaceutical performance for the full year 1994. Newly received European country approvals for the Company's proprietary dental products, Elyzol Dental Gel and Dumicoat, and their subsequent launch, will generate full-year revenue in l994 which will help offset the substantial investment in building the infrastructure for the Oral Health Care business.
 Other factors which may positively affect profits in 1994 include the anticipated receipt of new product approvals in U.S. Pharmaceuticals and European Oral Health Care, the consolidation of the pharmaceutical industry and health care reform in the United States, and the continued growth in the Company's Animal Health business which will be enhanced by a major expansion at its state-of-the-art fermentation facility, scheduled for completion by mid-l994.
 However, as last discussed on July 30, l993, there are factors which are having a negative impact on l993 results. These include adverse foreign currency effects and lower pricing in the Company's pharmaceutical businesses, slower than expected receipt of new product approvals both in Europe and the U.S., the substantial investment in building the infrastructure for the Oral Health Care business, and FDA's action related to its industry-wide request to discontinue marketing products containing iodinated glycerol. The Company believes that products containing iodinated glycerol should remain on the market. In this regard, the Company has proposed actions to the FDA that could allow the continuation of the marketing of these products. To date, the FDA has not responded to the Company's proposal.
 While actual results for the third quarter ending September 30, l993 will be released in early November, a review of preliminary results for the period indicates that the Company achieved revenue growth of over l8%, with its Barre-National unit contributing a substantial portion of the increase. However, due primarily to the effect of the negative factors discussed above and a change in the business mix of revenues, earnings per share in the third quarter of l993 will be less than half of the $.l3 per share from continuing operations reported last year. In assessing the fourth quarter, the Company believes it will be difficult to equal 1992's fourth quarter earnings, and that some of the issues that have influenced 1993 may carry over into next year.
 The Company is encouraged by many favorable developments and remains confident that all of the Company's efforts and investments are coming together for a more positive outlook in 1994. A. L. Laboratories is a multinational manufacturer and marketer of specialized and value-added, branded pharmaceuticals and animal health micronutrients, with plant sites in Illinois, Maryland, New Jersey, New York, North Carolina, Washington State, Denmark and Indonesia.
 -0- 10/18/93
 /CONTACT: Iris Daniels of A.L. Laboratories, 201-947-7774 or Donna Stein of Morgen Walke, 212-850-5600/
 (BMD)


CO: A. L. Laboratories ST: New Jersey IN: HEA SU:

WB -- NY084 -- 3583 10/18/93 16:51 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 18, 1993
Words:528
Previous Article:CERNER CORP. REPORTS RECORD THIRD QUARTER RESULTS
Next Article:BED BATH & BEYOND ANNOUNCES AGGREGATE SALE OF STOCK BY SHAREHOLDERS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters